Physician profile
Erick J Green
NPI 1821371022
$1,383.39
in general payments reported to CMS, 2019-2025
25 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $85.84 · 2021: $120 · 2022: $55.80 · 2023: $256 · 2024: $327 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $406.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $199.88 | 2019-2024 | Airsupra |
| Alk-Abello, INC | $125.00 | 2023 | |
| Octapharma USA, INC. | $114.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.91 | 2025 | |
| Pharming Healthcare, INC. | $44.77 | 2025 | Ruconest |
| Abbott Laboratories | $44.30 | 2025 | Id Now Instrument |
| Csl Behring | $42.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.76 | 2022 | |
| Ionis Pharmaceuticals, INC. | $27.41 | 2025 | Dawnzera |
| Optinose US, INC. | $23.85 | 2021 | |
| Amgen INC. | $23.69 | 2021 | |
| Genzyme Corporation | $21.94 | 2019 | |
| Biocryst US Sales Co., LLC | $21.41 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.04 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.38 | 2024 | Crysvita |
| Fidia Pharma USA INC. | $20.00 | 2025 | Hymovis |
| Takeda Pharmaceuticals U.S.A., INC. | $19.89 | 2021 | |
| Kaleo, INC. | $19.54 | 2019 | |
| Genentech USA, INC. | $18.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.43 | 2025 | Nuzyra |
| Bioventus LLC | $16.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2019 | |
| Nabriva Therapeutics, Plc | $13.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.